Diagnosis of placental insufficiency by testing f or serum DcR3

Malyshkina A.I., Sotnikova N.Yu., Kroshkina N.V., Batrak N.V.

1) V.N. Gorodkov Research Institute of Maternity and Childhood of Minzdrav of Russia, Ivanovo, Russia; 2) Ivanovo State Medical Academy of Minzdrav of Russia, Ivanovo, Russia
Aim. To investigate serum levels of DcR3 in women with threatened miscarriage, recurrent miscarriage, and healthy pregnancy.
Materials and methods. The study comprised 75 pregnant women, including 46 patients with a threatened miscarriage before12 weeks’ gestation and recurrent miscarriage (study group) and 29 women with a first-trimester pregnancy and no signs of threatened and recurrent miscarriage (control group). The serum level of DcR3 was determined by enzyme immunoassay.
Results. Serum levels of DcR3 above 0.87 pg/ml are indicative of the development of placental insufficiency in the second half of pregnancy, both in women of the study and control groups.
Conclusion. Elevated serum DcR3 levels in early pregnancy lend support for further studies aimed at predicting placental insufficiency.

Keywords

threatened miscarriage
recurrent miscarriage
placental insufficiency

References

  1. Стрижаков А.Н., Липатов И.С., Тезиков Ю.В. Плацентарная недостаточность. Самара: Офорт; 2014. 239с. [Strizhakov A.N., Lipatov I.S.,Tezikov Yu.V. Platsentarnaya nedostatochnost. Samara: Ofort; 2014. 239s].
  2. Батрак Н.В., Малышкина А.И., Сотникова Н.Ю., Крошкина Н.В. Клинико-иммунологические особенности беременных с привычным невынашиванием в анамнезе. Российский вестник акушера-гинеколога. 2015; 15(3): 35–9. [Batrak N.V., Malyshkina A.I., Sotnikova N.Yu., Kroshkina N.V. Kliniko-immunologicheskiye osobennosti beremennykh s privychnym nevynashivaniyem v anamneze. Rossiyskiy vestnik akushera-ginekologa/Russian obstetrician-gynecologist messenger. 2015; 15(3): 35–9. (in Russian)].
  3. Nadeau-Vallée M., Obari D., Palacios J., Brien M.È., Duval C., Chemtob S. et al. Sterile inflammation and pregnancy complications: a review. Reproduction. 2016; 152(6): R277-92. doi: 10.1530/REP-16-0453.
  4. Доброхотова Ю.Э., Ганковская Л.В., Бахарева И.В., Свитич О.А., Малушенко С.В., Магомедова А.М. Роль иммунных механизмов в патогенезе невынашивания беременности. Акушерство и гинекология. 2016; 7: 5-10. [Dobrokhotova Yu.E., Gankovskaya L.V., Bakhareva I.V., Svitich O.A., Malushenko S.V., Magomedova A.M. Rol immunnykh mekhanizmov v patogeneze nevynashivaniya beremennosti. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2016; 7: 5–10. http://dx.doi.org/10.18565/aig.2016.7.5-10. (in Russian)].
  5. Липатов И.С., Тезиков Ю.В., Линева О.И., Тютюнник В.Л., Кан Н.Е., Мартынова Н.В. и др. Патогенетические механизмы формирования плацентарной недостаточности и преэклампсии. Акушерство и гинекология. 2017; 9: 64–71. [Lipatov I.S., Tezikov Yu.V., Lineva O.I., Tyutyunnik V.L., Kan N.E., Martynova N.V. et al. Patogeneticheskiye mekhanizmy formirovaniya platsentarnoy nedostatochnosti i preeklampsii. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; 9: 64-71. (in Russian)]. http://dx.doi.org/10.18565/aig.2017.9.64-71
  6. Менжинская И.В., Ванько Л.В. Антифосфолипидные антитела как диагностические маркеры акушерского антифосфолипидного синдрома. Акушерство и гинекология. 2019; 2: 5–12. [Menzhinskaya I.V., Vanko L.V. Antifosfolipidnyye antitela kak diagnosticheskiye markery akusherskogo antifosfolipidnogo sindroma. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019; 2: 5-12. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.2.5-12
  7. Газиева И.А., Чистякова Г.Н., Ремизова И.И. Роль нарушений продукции цитокинов в генезе плацентарной недостаточности и ранних репродуктивных потерь. Медицинская иммунология. 2014; 16 (6): 539–50. [Gaziyeva I.A., Chistyakova G.N., Remizova I.I. Rol narusheniy produktsii tsitokinov v geneze platsentarnoy nedostatochnosti i rannikh reproduktivnykh poter. Meditsinskaya immunologiya/Medical immunology. 2014; 16 (6): 539–50. (in Russian)]. https://doi.org/10.15789/1563-0625-2014-6-539-550
  8. Кан Н.Е., Сироткина Е.А., Тютюнник В.Л., Высоких М.Ю., Курчакова Т.А., Володина М.А. и др. Особенности антиоксидантной защиты беременных в системе «мать-плацента-плод» при внутриутробной инфекции. Акушерство и гинекология. 2016; 1: 40–6. [Kan N.E., Sirotkina E.A., Tyutyunnik V.L., Vysokikh M.Yu., Kurchakova T.A., Volodina M.A. et al. Osobennosti antioksidantnoy zashchity beremennykh v sisteme «mat-platsenta-plod» pri vnutriutrobnoy infektsii. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2016; 1: 40–6. (in Russian)]. http://dx.doi.org/10.18565/aig.2016.1.40-46
  9. Булатова Ю.С., Тетруашвили Н.К., Вишнякова П.А., Высоких М.Ю., Марей М.В., Пятаева С.В., Сухих Г.Т. Митохондриальные белки микровезикул плазмы периферической крови как биомаркеры ранних потерь беременности. Акушерство и гинекология. 2017; 7: 46-51. [Bulatova Yu.S., Tetruashvili N.K.,Vishnyakova P.A., Vysokikh M.Yu., Marei M.V., Pyataeva S.V., Sukhikh G.T. Mitochondrial proteins of peripheral plasma microvesicles as biomarkers of early pregnancy losses. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (7): 46-51. (in Russian).http://dx.doi.org/10.18565/aig.2017.7.46-51
  10. Shomer E., Katzenell S., Zipori Y., Rebibo-Sabbah A., Brenner B., Aharon A. Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function. Thromb. Res. 2016; 137: 141–7. doi: 10.1016/j.thromres.2015.11.026.
  11. Булатова Ю.С., Тетруашвили Н.К., Вишнякова П.А., Высоких М.Ю., Марей М.В., Бобров М.Ю., Пятаева С.В. Митохондриальные белки микровезикул плазмы периферической крови как триггеры асептических воспалительных реакций у женщин с угрожающим и привычным выкидышем и физиологическим течением беременности. Акушерство и гинекология. 2018; 4: 42-8. [Bulatova Yu.S., Tetruashvili N.K., Vishnyakova P.A., Vysokikh M.Yu., Marei M.V., Bobrov M.Yu., Pyataeva S.V. Mitochondrial proteins of peripheral plasma microvesicles as triggers of aseptic inflammatory responses in women with threatened, recurrent abortion and physiological pregnancy. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (4): 42–8. (in Russian). https://dx.doi.org/10.18565/aig.2018.4.42-48
  12. Сухих Г.Т., Красный А.М., Кан Н.Е., Майорова Т.Д., Тютюнник В.Л., Ховхаева П.А. Сергунина О.А., Тютюнник Н.В., Грачева М.И., Вавина О.В., Озернюк Н.Д., Борис Д.А. Апоптоз и экспрессия ферментов антиоксидантной защиты в плаценте при преэклампсии. Акушерство и гинекология. 2015; 3: 11–5. [Sukhikh G.T., Krasnyi A.M., Kan N.E., Maiorova T.D., Tyutyunnik V.L., Khovkhaeva P.A., Sergunina O.A., Tyutyunnik N.V., Gracheva M.I., Vavina O.V., Ozernyuk N.D., Boris D.A. Placental apoptosis and antioxidant defense enzyme gene expression in preeclampsia. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; 3: 11–15. (in Russian)].
  13. Газиева И.А., Чистякова Г.Н., Ремизова И.И. Предикторная значимость показателей функционального состояния эндотелия и регуляции ангиогенеза в I триместре беременности в развитии плацентарной недостаточности и ранних репродуктивных потерь. Вопросы гинекологии, акушерства и перинатологии. 2015; 14 (2): 14–23. [Gaziyeva I.A., Chistyakova G.N., Remizova I.I. Prediktornaya znachimost pokazateley funktsionalnogo sostoyaniya endoteliya i regulyatsii angiogeneza v I trimestre beremennosti v razvitii platsentarnoy nedostatochnosti i rannikh reproduktivnykh poter. Voprosy ginekologii. akusherstva i perinatologii/Questions of gynecology, obstetrics and perinatology. 2015; 14 (2): 14-23 (in Russian)].
  14. Сотникова Н.Ю., Малышкина А.И., Крошкина Н.В., Батрак Н.В. Особенности регуляции fas-зависимого апоптоза при привычном невынашивании беременности ранних сроков. Российский иммунологический журнал. 2017; 11(20) (3): 510–2. [Sotnikova N. Yu., Malyshkina A.I., Kroshkina N.V., Batrak N.V. The regulation of fas-dependent apoptosis in rsa pregnancy. Rossiyskiy immunologicheskiy zhurnal/Russian journal of immunology. 2017. 2017; 11(20) (3): 510–2. (in Russian)]. eLIBRARY ID: 29972496
  15. Крошкина Н.В., Батрак Н.В. Особенности сывороточного содержания dcr3 на ранних сроках беременности при привычном невынашивании. Медицинская иммунология. 2017. Т. 19. № S. С. 264. [Kroshkina N.V., Batrak N.V. Osobennosti syvorotochnogo soderzhaniya DcR3 na rannikh srokakh beremennosti pri privychnom nevynashivanii. Meditsinskaya immunologiya/Medical immunology. 2017; 19: 264. (in Russian)].
  16. Siakavellas S.I., Sfikakis P.P., Bamias G. The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. Semin. Arthritis Rheum. 2015; 45(1): 1–8. doi: 10.1016/j.semarthrit.2015.02.007.
  17. Fukuda K., Miura Y., Maeda T., Hayashi S., Kurosaka M. Interleukin12B is upregulated by decoy receptor 3 in rheumatoid synovial fibroblasts. Mol. Med. Rep. 2016; 13(4): 3647–52. doi: 10.3892/mmr.2016.4985.
  18. Im J., Kim K., Hergert P., Nho R.S. Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3. J. Pathol. 2016; 240(1): 25–37. doi: 10.1002/path.4749.
  19. Lin C.K., Ting C.C., Tsai W.C., Chen Y.W., Hueng D.Y. A tissue microarray study of toll-like receptor 4, decoy receptor 3, and external signal regulated kinase 1/2 expressions in astrocytoma. Indian J Pathol Microbiol. 2016; 59(3): 294–300. doi: 10.4103/0377-4929.
  20. Jiang M., Lin X., He R., Lin X., Liang L., Tang R., et al. Decoy receptor 3 (DcR3) as a biomarker of tumor deterioration in female reproductive cancers: a meta-analysis. Med. Sci. Monit. 2016; 22: 1850–7. doi: 10.12659/msm.896226.
  21. Liu J., Zhao Z., Zou Y., Zhang M., Zhou Y., Li Y., et al. The expression of death decoy receptor 3 was increased in the patients with primary Sjogren’s syndrome. Clin. Rheumatol. 2015; 34(5): 879–85. doi: 10.1007/s10067-014-2853-2.
  22. Xiu Z., Shen H., Tian Y., Xia L., Lu J. Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis. Cytokine. 2015; 72(2): 185–9. doi: 10.1016/j.cyto.2014.12.026.
  23. Chang T.Y., Hsu C.Y., Huang P.H., Chiang C.H., Leu H.B., Huang C.C., et al.Usefulness of circulating decoy receptor 3 in predicting coronary artery disease severity and future major adverse cardiovascular events in patients with multivessel coronary artery disease. Am. J. Cardiol. 2015; 116(7): 1028–33. doi: 10.1016/j.amjcard.2015.06.041.
  24. Chen M.H., Kan H.T., Liu C.Y., Yu W.K., Lee S.S., Wang J.H., et al. Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. J Formos Med Assoc. 2017; 116(1): 49–56. doi: 10.1016/j.jfma.2016.01.007.
  25. Maruyama H., Hirayama K., Nagai M., Ebihara I., Shimohata H., Kobayashi M. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis. Clin. Rheumatol. 2016; 35(10): 2469–76. doi: 10.1007/s10067-016-3321-y.
  26. Zhang Y., Huang S., Leng Y., Chen X., Liu T., Wang H., et al. Effect of DcR3-specific siRNA on cell growth suppression and apoptosis induction in glioma cells via affecting ERK and AKT. Onco. Targets Ther. 2016; 9: 5195–202. doi: 10.2147/OTT.S108395.
  27. Zhang Y., Li D., Zhao X., Song S., Zhang L., Zhu D., et al. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2015; 463(4): 1144–51. doi: 10.1016/j.bbrc.2015.06.074.
  28. Liu Y.L., Chen W.T., Lin Y.Y., Lu P.H., Hsieh S.L., Cheng I.H. Amelioration of amyloid-beta-induced deficits by DcR3 in an Alzheimer’s disease model. Mol. Neurodegener. 2017; 12(1): 30. doi: 10.1186/s13024-017-0173-0.
  29. Yeh C.C., Yang M.J., Lussier E.C., Tsai H.W., Lo P.F., Hsieh S.L. et al. Low plasma levels of decoy receptor 3 (DcR3) in the third trimester of pregnancy with preeclampsia. Taiwan. J. Obstet. Gynecol. 2019; 58(3): 349-353. doi: 10.1016/j.tjog.2019.03.011.
  30. Wang W., Parchim N.F., Iriyama T., Luo R., Zhao C., Liu C. et al. Excess LIGHT contributes to placental impairment increased secretion of vasoactive factors, hypertension and proteinuria in preeclampsia. Hypertension. 2014; 63(3): 595–606. doi: 10.1161/HYPERTENSIONAHA.113.02458.

Received 19.11.2019

Accepted 29.11.2019

About the Authors

Anna I. Malyshkina, MD, director Federal state budgetary institution Ivanovo research institute of motherhood and childhood of a name of V. N. Gorodkov of Ministry
of health of the Russian Federation.; head department of obstetrics and gynecology, medical genetics, Federal state budgetary educational institution of higher education Ivanovo state medical academy of the Ministry of health of the Russian Federation. E-mail: ivniimid@inbox.ru
153045, Russia, Ivanovo, Pobedy St., 20; 153012, Russia, Ivanovo, Sheremetevsky Ave., 8.
Natalya Yu. Sotnikova, MD, professor, honored doctor of the Russian Federation, head of the laboratory of clinical immunology, Federal state budgetary institution Ivanovo research institute of motherhood and childhood of a name of V. N. Gorodkov of Ministry of health of the Russian Federation. department of pathophysiology and immunology, Federal state budgetary educational institution of higher education Ivanovo state medical academy of the Ministry of health of the Russian Federation.
E-mail: ivniimid@inbox.ru
153045, Russia, Ivanovo, Pobedy St., 20; 153012, Russia, Ivanovo, Sheremetevsky Ave., 8.
Natalya V. Kroshkina, Ph.D., researcher, Federal state budgetary institution Ivanovo research institute of motherhood and childhood of a name of V. N. Gorodkov
of Ministry of health of the Russian Federation. Phone: +7(980)6931822. E-mail: ivniimid@inbox.ru
153045, Russia, Ivanovo, Pobedy St., 20.
Nataliya V. Batrak, PhD, assistant to department of obstetrics and gynecology, medical genetics, Federal state budgetary educational institution of higher education Ivanovo state medical academy of the Ministry of health of the Russian Federation. Phone: +7(962)1600133. E-mail: batrakn@inbox.ru. https://orcid.org/0000-0002-5230-9961
153012, Russia, Ivanovo, Sheremetevsky Ave., 8.

For citation: Malyshkina A.I., Sotnikova N.Yu., Kroshkina N.V., Batrak N.V. Diagnosis of placental insufficiency by testing for serum DcR3.
Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2020; 3: 64-70. (In Russian).
https://dx.doi.org/10.18565/aig.2020.3.64-70

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.